APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ulcerative Colitis Medicine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Ulcerative Colitis Medicine Market Analysis and Forecast 2026-2032

4 January 2026196 pages

Choose your research edition.

Industry ResearchUlcerative Colitis Medicine Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Ulcerative Colitis Medicine Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Ulcerative Colitis Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ulcerative Colitis Medicine Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Ulcerative Colitis Medicine Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Ulcerative Colitis Medicine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Ulcerative Colitis Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Ulcerative Colitis Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Ulcerative Colitis Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Ulcerative Colitis Medicine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Ulcerative Colitis Medicine include Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson and Johnson, GSK, AstraZeneca and Cipla, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Ulcerative Colitis Medicine, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Ulcerative Colitis Medicine, also provides the revenue of main regions and countries. Of the upcoming market potential for Ulcerative Colitis Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ulcerative Colitis Medicine revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Ulcerative Colitis Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Ulcerative Colitis Medicine revenue, projected growth trends, production technology, application and end-user industry.

Ulcerative Colitis Medicine Segment by Company

Sumitomo

Pfizer

Novartis

Merck

Sanofi

Johnson and Johnson

GSK

AstraZeneca

Cipla

Sun Pharm

Allergan

Teva Pharmaceutical

Ulcerative Colitis Medicine Segment by Type

5-Aminosalicylic Acid

Corticosteroids

Immunomodulator Drugs

Biologics

Ulcerative Colitis Medicine Segment by Application

Ulcerative Proctitis

Proctosigmoiditis

Left-Sided Colitis

Pancolitis

Acute Severe Ulcerative Colitis

Ulcerative Colitis Medicine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ulcerative Colitis Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ulcerative Colitis Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ulcerative Colitis Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Ulcerative Colitis Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Ulcerative Colitis Medicine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Ulcerative Colitis Medicine revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Ulcerative Colitis Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 5-Aminosalicylic Acid Major Player Table 3. Corticosteroids Major Player Table 4. Immunomodulator Drugs Major Player Table 5. Biologics Major Player Table 6. Global Ulcerative Colitis Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Ulcerative Proctitis Major Player Table 8. Proctosigmoiditis Major Player Table 9. Left-Sided Colitis Major Player Table 10. Pancolitis Major Player Table 11. Acute Severe Ulcerative Colitis Major Player Table 12. Ulcerative Colitis Medicine Industry Trends Table 13. Ulcerative Colitis Medicine Industry Drivers Table 14. Ulcerative Colitis Medicine Industry Opportunities and Challenges Table 15. Ulcerative Colitis Medicine Industry Restraints Table 16. Global Ulcerative Colitis Medicine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Ulcerative Colitis Medicine Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Ulcerative Colitis Medicine Market Share by Region (2021-2026) Table 19. Global Ulcerative Colitis Medicine Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Ulcerative Colitis Medicine Market Share by Region (2027-2032) Table 21. Global Ulcerative Colitis Medicine Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Ulcerative Colitis Medicine Revenue Market Share by Players (2021-2026) Table 23. Global Ulcerative Colitis Medicine Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Ulcerative Colitis Medicine Key Players Headquarters & Area Served Table 25. Global Ulcerative Colitis Medicine Players, Product Type & Application Table 26. Global Ulcerative Colitis Medicine Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Ulcerative Colitis Medicine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Ulcerative Colitis Medicine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Ulcerative Colitis Medicine Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Ulcerative Colitis Medicine Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Ulcerative Colitis Medicine Revenue Market Share by Type (2021-2026) Table 33. Global Ulcerative Colitis Medicine Revenue Market Share by Type (2027-2032) Table 34. Global Ulcerative Colitis Medicine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Ulcerative Colitis Medicine Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Ulcerative Colitis Medicine Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Ulcerative Colitis Medicine Revenue Market Share by Application (2021-2026) Table 38. Global Ulcerative Colitis Medicine Revenue Market Share by Application (2027-2032) Table 39. Sumitomo Company Information Table 40. Sumitomo Business Overview Table 41. Sumitomo Ulcerative Colitis Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Sumitomo Ulcerative Colitis Medicine Product Portfolio Table 43. Sumitomo Recent Development Table 44. Pfizer Company Information Table 45. Pfizer Business Overview Table 46. Pfizer Ulcerative Colitis Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Pfizer Ulcerative Colitis Medicine Product Portfolio Table 48. Pfizer Recent Development Table 49. Novartis Company Information Table 50. Novartis Business Overview Table 51. Novartis Ulcerative Colitis Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Novartis Ulcerative Colitis Medicine Product Portfolio Table 53. Novartis Recent Development Table 54. Merck Company Information Table 55. Merck Business Overview Table 56. Merck Ulcerative Colitis Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Merck Ulcerative Colitis Medicine Product Portfolio Table 58. Merck Recent Development Table 59. Sanofi Company Information Table 60. Sanofi Business Overview Table 61. Sanofi Ulcerative Colitis Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Sanofi Ulcerative Colitis Medicine Product Portfolio Table 63. Sanofi Recent Development Table 64. Johnson and Johnson Company Information Table 65. Johnson and Johnson Business Overview Table 66. Johnson and Johnson Ulcerative Colitis Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Johnson and Johnson Ulcerative Colitis Medicine Product Portfolio Table 68. Johnson and Johnson Recent Development Table 69. GSK Company Information Table 70. GSK Business Overview Table 71. GSK Ulcerative Colitis Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. GSK Ulcerative Colitis Medicine Product Portfolio Table 73. GSK Recent Development Table 74. AstraZeneca Company Information Table 75. AstraZeneca Business Overview Table 76. AstraZeneca Ulcerative Colitis Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. AstraZeneca Ulcerative Colitis Medicine Product Portfolio Table 78. AstraZeneca Recent Development Table 79. Cipla Company Information Table 80. Cipla Business Overview Table 81. Cipla Ulcerative Colitis Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Cipla Ulcerative Colitis Medicine Product Portfolio Table 83. Cipla Recent Development Table 84. Sun Pharm Company Information Table 85. Sun Pharm Business Overview Table 86. Sun Pharm Ulcerative Colitis Medicine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Sun Pharm Ulcerative Colitis Medicine Product Portfolio Table 88. Sun Pharm Recent Development Table 89. Allergan Company Information Table 90. Allergan Business Overview Table 91. Allergan Ulcerative Colitis Medicine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Allergan Ulcerative Colitis Medicine Product Portfolio Table 93. Allergan Recent Development Table 94. Teva Pharmaceutical Company Information Table 95. Teva Pharmaceutical Business Overview Table 96. Teva Pharmaceutical Ulcerative Colitis Medicine Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Teva Pharmaceutical Ulcerative Colitis Medicine Product Portfolio Table 98. Teva Pharmaceutical Recent Development Table 99. North America Ulcerative Colitis Medicine Revenue by Type (2021-2026) & (US$ Million) Table 100. North America Ulcerative Colitis Medicine Revenue by Type (2027-2032) & (US$ Million) Table 101. North America Ulcerative Colitis Medicine Revenue by Application (2021-2026) & (US$ Million) Table 102. North America Ulcerative Colitis Medicine Revenue by Application (2027-2032) & (US$ Million) Table 103. North America Ulcerative Colitis Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. North America Ulcerative Colitis Medicine Revenue by Country (2021-2026) & (US$ Million) Table 105. North America Ulcerative Colitis Medicine Revenue by Country (US$ Million) & (2027-2032) Table 106. Europe Ulcerative Colitis Medicine Revenue by Type (2021-2026) & (US$ Million) Table 107. Europe Ulcerative Colitis Medicine Revenue by Type (2027-2032) & (US$ Million) Table 108. Europe Ulcerative Colitis Medicine Revenue by Application (2021-2026) & (US$ Million) Table 109. Europe Ulcerative Colitis Medicine Revenue by Application (2027-2032) & (US$ Million) Table 110. Europe Ulcerative Colitis Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. Europe Ulcerative Colitis Medicine Revenue by Country (2021-2026) & (US$ Million) Table 112. Europe Ulcerative Colitis Medicine Revenue by Country (US$ Million) & (2027-2032) Table 113. China Ulcerative Colitis Medicine Revenue by Type (2021-2026) & (US$ Million) Table 114. China Ulcerative Colitis Medicine Revenue by Type (2027-2032) & (US$ Million) Table 115. China Ulcerative Colitis Medicine Revenue by Application (2021-2026) & (US$ Million) Table 116. China Ulcerative Colitis Medicine Revenue by Application (2027-2032) & (US$ Million) Table 117. Asia Ulcerative Colitis Medicine Revenue by Type (2021-2026) & (US$ Million) Table 118. Asia Ulcerative Colitis Medicine Revenue by Type (2027-2032) & (US$ Million) Table 119. Asia Ulcerative Colitis Medicine Revenue by Application (2021-2026) & (US$ Million) Table 120. Asia Ulcerative Colitis Medicine Revenue by Application (2027-2032) & (US$ Million) Table 121. Asia Ulcerative Colitis Medicine Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Asia Ulcerative Colitis Medicine Revenue by Region (US$ Million) & (2021-2026) Table 123. Asia Ulcerative Colitis Medicine Revenue by Region (US$ Million) & (2027-2032) Table 124. SAMEA Ulcerative Colitis Medicine Revenue by Type (2021-2026) & (US$ Million) Table 125. SAMEA Ulcerative Colitis Medicine Revenue by Type (2027-2032) & (US$ Million) Table 126. SAMEA Ulcerative Colitis Medicine Revenue by Application (2021-2026) & (US$ Million) Table 127. SAMEA Ulcerative Colitis Medicine Revenue by Application (2027-2032) & (US$ Million) Table 128. SAMEA Ulcerative Colitis Medicine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. SAMEA Ulcerative Colitis Medicine Revenue by Country (2021-2026) & (US$ Million) Table 130. SAMEA Ulcerative Colitis Medicine Revenue by Country (US$ Million) & (2027-2032) Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Ulcerative Colitis Medicine Image Figure 2. Global Ulcerative Colitis Medicine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ulcerative Colitis Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 4. 5-Aminosalicylic Acid Image Figure 5. Corticosteroids Image Figure 6. Immunomodulator Drugs Image Figure 7. Biologics Image Figure 8. Global Ulcerative Colitis Medicine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Ulcerative Colitis Medicine Market Size Share 2021 VS 2025 VS 2032 Figure 10. Ulcerative Proctitis Image Figure 11. Proctosigmoiditis Image Figure 12. Left-Sided Colitis Image Figure 13. Pancolitis Image Figure 14. Acute Severe Ulcerative Colitis Image Figure 15. Global Ulcerative Colitis Medicine Market Size (US$ Million) & (2021-2032) Figure 16. Global Ulcerative Colitis Medicine Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Ulcerative Colitis Medicine Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Ulcerative Colitis Medicine Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Ulcerative Colitis Medicine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Ulcerative Colitis Medicine Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Ulcerative Colitis Medicine Revenue Market Share by Type (2021-2032) Figure 23. Global Ulcerative Colitis Medicine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Ulcerative Colitis Medicine Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Ulcerative Colitis Medicine Revenue Market Share by Application (2021-2032) Figure 26. North America Ulcerative Colitis Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Ulcerative Colitis Medicine Revenue Share by Type (2021-2032) Figure 28. North America Ulcerative Colitis Medicine Revenue Share by Application (2021-2032) Figure 29. North America Ulcerative Colitis Medicine Revenue Share by Country (2021-2032) Figure 30. United States Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Ulcerative Colitis Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Ulcerative Colitis Medicine Revenue Share by Type (2021-2032) Figure 35. Europe Ulcerative Colitis Medicine Revenue Share by Application (2021-2032) Figure 36. Europe Ulcerative Colitis Medicine Revenue Share by Country (2021-2032) Figure 37. Germany Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Ulcerative Colitis Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Ulcerative Colitis Medicine Revenue Share by Type (2021-2032) Figure 47. China Ulcerative Colitis Medicine Revenue Share by Application (2021-2032) Figure 48. Asia Ulcerative Colitis Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Ulcerative Colitis Medicine Revenue Share by Type (2021-2032) Figure 50. Asia Ulcerative Colitis Medicine Revenue Share by Application (2021-2032) Figure 51. Asia Ulcerative Colitis Medicine Revenue Share by Region (2021-2032) Figure 52. Japan Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Ulcerative Colitis Medicine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Ulcerative Colitis Medicine Revenue Share by Type (2021-2032) Figure 60. SAMEA Ulcerative Colitis Medicine Revenue Share by Application (2021-2032) Figure 61. SAMEA Ulcerative Colitis Medicine Revenue Share by Country (2021-2032) Figure 62. Brazil Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Ulcerative Colitis Medicine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • 5-Aminosalicylic Acid
  • Corticosteroids
  • Immunomodulator Drugs
  • Biologics
Applications
  • Ulcerative Proctitis
  • Proctosigmoiditis
  • Left-Sided Colitis
  • Pancolitis
  • Acute Severe Ulcerative Colitis
Companies covered
  • Sumitomo
  • Pfizer
  • Novartis
  • Merck
  • Sanofi
  • Johnson and Johnson
  • GSK
  • AstraZeneca
  • Cipla
  • Sun Pharm
  • Allergan
  • Teva Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Ulcerative Colitis Medicine Market by Type
  3. 1.2.1 Global Ulcerative Colitis Medicine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 5-Aminosalicylic Acid
  5. 1.2.3 Corticosteroids
  6. 1.2.4 Immunomodulator Drugs
  7. 1.2.5 Biologics
  8. 1.3 Ulcerative Colitis Medicine Market by Application
  9. 1.3.1 Global Ulcerative Colitis Medicine Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Ulcerative Proctitis
  11. 1.3.3 Proctosigmoiditis
  12. 1.3.4 Left-Sided Colitis
  13. 1.3.5 Pancolitis
  14. 1.3.6 Acute Severe Ulcerative Colitis
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Ulcerative Colitis Medicine Market Dynamics
  1. 2.1 Ulcerative Colitis Medicine Industry Trends
  2. 2.2 Ulcerative Colitis Medicine Industry Drivers
  3. 2.3 Ulcerative Colitis Medicine Industry Opportunities and Challenges
  4. 2.4 Ulcerative Colitis Medicine Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Ulcerative Colitis Medicine Market Perspective (2021-2032)
  2. 3.2 Global Ulcerative Colitis Medicine Growth Trends by Region
  3. 3.2.1 Global Ulcerative Colitis Medicine Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Ulcerative Colitis Medicine Market Size by Region (2021-2026)
  5. 3.2.3 Global Ulcerative Colitis Medicine Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Ulcerative Colitis Medicine Revenue by Players
  2. 4.1.1 Global Ulcerative Colitis Medicine Revenue by Players (2021-2026)
  3. 4.1.2 Global Ulcerative Colitis Medicine Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Ulcerative Colitis Medicine Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Ulcerative Colitis Medicine Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Ulcerative Colitis Medicine Key Players Headquarters & Area Served
  7. 4.4 Global Ulcerative Colitis Medicine Players, Product Type & Application
  8. 4.5 Global Ulcerative Colitis Medicine Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Ulcerative Colitis Medicine Market CR5 and HHI
  11. 4.6.3 2025 Ulcerative Colitis Medicine Tier 1, Tier 2, and Tier 3
5 Ulcerative Colitis Medicine Market Size by Type
  1. 5.1 Global Ulcerative Colitis Medicine Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Ulcerative Colitis Medicine Revenue by Type (2021-2032)
  3. 5.3 Global Ulcerative Colitis Medicine Revenue Market Share by Type (2021-2032)
6 Ulcerative Colitis Medicine Market Size by Application
  1. 6.1 Global Ulcerative Colitis Medicine Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Ulcerative Colitis Medicine Revenue by Application (2021-2032)
  3. 6.3 Global Ulcerative Colitis Medicine Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sumitomo
  2. 7.1.1 Sumitomo Company Information
  3. 7.1.2 Sumitomo Business Overview
  4. 7.1.3 Sumitomo Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sumitomo Ulcerative Colitis Medicine Product Portfolio
  6. 7.1.5 Sumitomo Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Ulcerative Colitis Medicine Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Ulcerative Colitis Medicine Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck Ulcerative Colitis Medicine Product Portfolio
  24. 7.4.5 Merck Recent Developments
  25. 7.5 Sanofi
  26. 7.5.1 Sanofi Company Information
  27. 7.5.2 Sanofi Business Overview
  28. 7.5.3 Sanofi Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sanofi Ulcerative Colitis Medicine Product Portfolio
  30. 7.5.5 Sanofi Recent Developments
  31. 7.6 Johnson and Johnson
  32. 7.6.1 Johnson and Johnson Company Information
  33. 7.6.2 Johnson and Johnson Business Overview
  34. 7.6.3 Johnson and Johnson Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Johnson and Johnson Ulcerative Colitis Medicine Product Portfolio
  36. 7.6.5 Johnson and Johnson Recent Developments
  37. 7.7 GSK
  38. 7.7.1 GSK Company Information
  39. 7.7.2 GSK Business Overview
  40. 7.7.3 GSK Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GSK Ulcerative Colitis Medicine Product Portfolio
  42. 7.7.5 GSK Recent Developments
  43. 7.8 AstraZeneca
  44. 7.8.1 AstraZeneca Company Information
  45. 7.8.2 AstraZeneca Business Overview
  46. 7.8.3 AstraZeneca Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  47. 7.8.4 AstraZeneca Ulcerative Colitis Medicine Product Portfolio
  48. 7.8.5 AstraZeneca Recent Developments
  49. 7.9 Cipla
  50. 7.9.1 Cipla Company Information
  51. 7.9.2 Cipla Business Overview
  52. 7.9.3 Cipla Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Cipla Ulcerative Colitis Medicine Product Portfolio
  54. 7.9.5 Cipla Recent Developments
  55. 7.10 Sun Pharm
  56. 7.10.1 Sun Pharm Company Information
  57. 7.10.2 Sun Pharm Business Overview
  58. 7.10.3 Sun Pharm Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Sun Pharm Ulcerative Colitis Medicine Product Portfolio
  60. 7.10.5 Sun Pharm Recent Developments
  61. 7.11 Allergan
  62. 7.11.1 Allergan Company Information
  63. 7.11.2 Allergan Business Overview
  64. 7.11.3 Allergan Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Allergan Ulcerative Colitis Medicine Product Portfolio
  66. 7.11.5 Allergan Recent Developments
  67. 7.12 Teva Pharmaceutical
  68. 7.12.1 Teva Pharmaceutical Company Information
  69. 7.12.2 Teva Pharmaceutical Business Overview
  70. 7.12.3 Teva Pharmaceutical Ulcerative Colitis Medicine Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Teva Pharmaceutical Ulcerative Colitis Medicine Product Portfolio
  72. 7.12.5 Teva Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Ulcerative Colitis Medicine Revenue (2021-2032)
  2. 8.2 North America Ulcerative Colitis Medicine Revenue by Type (2021-2032)
  3. 8.2.1 North America Ulcerative Colitis Medicine Revenue by Type (2021-2026)
  4. 8.2.2 North America Ulcerative Colitis Medicine Revenue by Type (2027-2032)
  5. 8.3 North America Ulcerative Colitis Medicine Revenue Share by Type (2021-2032)
  6. 8.4 North America Ulcerative Colitis Medicine Revenue by Application (2021-2032)
  7. 8.4.1 North America Ulcerative Colitis Medicine Revenue by Application (2021-2026)
  8. 8.4.2 North America Ulcerative Colitis Medicine Revenue by Application (2027-2032)
  9. 8.5 North America Ulcerative Colitis Medicine Revenue Share by Application (2021-2032)
  10. 8.6 North America Ulcerative Colitis Medicine Revenue by Country
  11. 8.6.1 North America Ulcerative Colitis Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Ulcerative Colitis Medicine Revenue by Country (2021-2026)
  13. 8.6.3 North America Ulcerative Colitis Medicine Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Ulcerative Colitis Medicine Revenue (2021-2032)
  2. 9.2 Europe Ulcerative Colitis Medicine Revenue by Type (2021-2032)
  3. 9.2.1 Europe Ulcerative Colitis Medicine Revenue by Type (2021-2026)
  4. 9.2.2 Europe Ulcerative Colitis Medicine Revenue by Type (2027-2032)
  5. 9.3 Europe Ulcerative Colitis Medicine Revenue Share by Type (2021-2032)
  6. 9.4 Europe Ulcerative Colitis Medicine Revenue by Application (2021-2032)
  7. 9.4.1 Europe Ulcerative Colitis Medicine Revenue by Application (2021-2026)
  8. 9.4.2 Europe Ulcerative Colitis Medicine Revenue by Application (2027-2032)
  9. 9.5 Europe Ulcerative Colitis Medicine Revenue Share by Application (2021-2032)
  10. 9.6 Europe Ulcerative Colitis Medicine Revenue by Country
  11. 9.6.1 Europe Ulcerative Colitis Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Ulcerative Colitis Medicine Revenue by Country (2021-2026)
  13. 9.6.3 Europe Ulcerative Colitis Medicine Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Ulcerative Colitis Medicine Revenue (2021-2032)
  2. 10.2 China Ulcerative Colitis Medicine Revenue by Type (2021-2032)
  3. 10.2.1 China Ulcerative Colitis Medicine Revenue by Type (2021-2026)
  4. 10.2.2 China Ulcerative Colitis Medicine Revenue by Type (2027-2032)
  5. 10.3 China Ulcerative Colitis Medicine Revenue Share by Type (2021-2032)
  6. 10.4 China Ulcerative Colitis Medicine Revenue by Application (2021-2032)
  7. 10.4.1 China Ulcerative Colitis Medicine Revenue by Application (2021-2026)
  8. 10.4.2 China Ulcerative Colitis Medicine Revenue by Application (2027-2032)
  9. 10.5 China Ulcerative Colitis Medicine Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Ulcerative Colitis Medicine Revenue (2021-2032)
  2. 11.2 Asia Ulcerative Colitis Medicine Revenue by Type (2021-2032)
  3. 11.2.1 Asia Ulcerative Colitis Medicine Revenue by Type (2021-2026)
  4. 11.2.2 Asia Ulcerative Colitis Medicine Revenue by Type (2027-2032)
  5. 11.3 Asia Ulcerative Colitis Medicine Revenue Share by Type (2021-2032)
  6. 11.4 Asia Ulcerative Colitis Medicine Revenue by Application (2021-2032)
  7. 11.4.1 Asia Ulcerative Colitis Medicine Revenue by Application (2021-2026)
  8. 11.4.2 Asia Ulcerative Colitis Medicine Revenue by Application (2027-2032)
  9. 11.5 Asia Ulcerative Colitis Medicine Revenue Share by Application (2021-2032)
  10. 11.6 Asia Ulcerative Colitis Medicine Revenue by Country
  11. 11.6.1 Asia Ulcerative Colitis Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Ulcerative Colitis Medicine Revenue by Country (2021-2026)
  13. 11.6.3 Asia Ulcerative Colitis Medicine Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Ulcerative Colitis Medicine Revenue (2021-2032)
  2. 12.2 SAMEA Ulcerative Colitis Medicine Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Ulcerative Colitis Medicine Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Ulcerative Colitis Medicine Revenue by Type (2027-2032)
  5. 12.3 SAMEA Ulcerative Colitis Medicine Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Ulcerative Colitis Medicine Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Ulcerative Colitis Medicine Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Ulcerative Colitis Medicine Revenue by Application (2027-2032)
  9. 12.5 SAMEA Ulcerative Colitis Medicine Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Ulcerative Colitis Medicine Revenue by Country
  11. 12.6.1 SAMEA Ulcerative Colitis Medicine Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Ulcerative Colitis Medicine Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Ulcerative Colitis Medicine Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst